Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic

Fabio Pires de Souza Santos; Renato Sampaio Tavares; Katia Borgia Barbosa Pagnano

doi:10.1016/j.htct.2020.06.005

Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic

Hematol Transfus Cell Ther. 2020 Jul-Sep;42(3):195-199. doi: 10.1016/j.htct.2020.06.005. Epub 2020 Jun 19.

Authors

Fabio Pires de Souza Santos¹, Renato Sampaio Tavares², Katia Borgia Barbosa Pagnano³

Affiliations

¹ Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Hospital BP Mirante, São Paulo, SP, Brazil.
² Hospital das Clínicas da Universidade Federal de Goiás (HC UFG), Goiania, GO, Brazil. Electronic address: renatosampaiotavares@gmail.com.
³ Centro de Hematologia e Hemoterapia, Universidade Estadual de Campinas (Hemocentro Unicamp), Campinas, SP, Brazil.

Abstract

The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay. This guideline aims to give providers a sense of direction in order to better take care of patients and prioritize care.

Keywords: Chronic myeloproliferative neoplasms; Novel coronavirus; SARS-CoV2 pandemic.